NIH oncology peer reviewers are protesting the outcome of a recent meeting in which their own grant applications fared so poorly that the reviewers said they were penalized for their service.
Also in this 8-page issue: FISH assay predicts survival on Iressa, Univ. of Colorado Cancer Center study finds.
FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care









